collection
https://read.qxmd.com/read/25940537/rivaroxaban-in-antiphospholipid-syndrome-raps-protocol-a-prospective-randomized-controlled-phase-ii-iii-clinical-trial-of-rivaroxaban-versus-warfarin-in-patients-with-thrombotic-antiphospholipid-syndrome-with-or-without-sle
#41
RANDOMIZED CONTROLLED TRIAL
H Cohen, C J Doré, S Clawson, B J Hunt, D Isenberg, M Khamashta, N Muirhead
INTRODUCTION: The current mainstay of the treatment of thrombotic antiphospholipid syndrome (APS) is long-term anticoagulation with vitamin K antagonists (VKAs) such as warfarin. Non-VKA oral anticoagulants (NOACs), which include rivaroxaban, have been shown to be effective and safe compared with warfarin for the treatment of venous thromboembolism (VTE) in major phase III prospective, randomized controlled trials (RCTs), but the results may not be directly generalizable to patients with APS...
September 2015: Lupus
https://read.qxmd.com/read/25619266/acute-pulmonary-embolism-risk-assessment-risk-stratification-and-treatment-options
#42
REVIEW
Franco Piovella, Diana Irina Iosub
INTRODUCTION: Pulmonary embolism (PE) is a potentially life-threatening cardiovascular emergency with a high mortality rate. Rapid diagnosis and treatment are important in optimising clinical outcomes in patients with PE, and anticoagulants are the mainstay of treatment. Traditionally, anticoagulant therapy involves parenteral anticoagulants, overlapping with and followed by oral vitamin K antagonists. Direct oral anticoagulants (DOACs), including the factor Xa inhibitors rivaroxaban, apixaban and edoxaban, and the direct thrombin inhibitor dabigatran etexilate, have been developed to address limitations associated with traditional anticoagulant therapy...
September 2016: Clinical Respiratory Journal
https://read.qxmd.com/read/25620711/embolic-stroke-during-apixaban-therapy-for-left-atrial-appendage-thrombus
#43
JOURNAL ARTICLE
Masaki Ohyagi, Kazuha Nakamura, Mutsufusa Watanabe, Hiroto Fujigasaki
Left atrial appendage (LAA) thrombus is associated with atrial fibrillation (AF) and is a powerful predictor of cardiogenic thromboembolism. Warfarin is an established anticoagulant therapy for patients with LAA thrombus to prevent thromboembolic complications. Apixaban is superior to warfarin in the prevention of thromboembolic complications in patients with AF, and there are case reports showing apixaban-associated resolution of LAA thrombus; however, the efficacy and safety of apixaban for the treatment of LAA thrombus remains unproven...
April 2015: Journal of Stroke and Cerebrovascular Diseases: the Official Journal of National Stroke Association
https://read.qxmd.com/read/25634169/efficacy-and-safety-of-oral-anticoagulants-versus-aspirin-for-patients-with-atrial-fibrillation-a-meta-analysis
#44
REVIEW
Jing-Tao Zhang, Ke-Ping Chen, Shu Zhang
The purpose of this study was to perform a meta-analysis comparing the effectiveness and safety of anticoagulation to antiplatelet therapy for the prevention of thromboembolic events in patients with atrial fibrillation (AF). MEDLINE, Cochrane, EMBASE, and Google Scholar databases were searched for studies published through May 31, 2014. Randomized controlled trials comparing anticoagulants (warfarin) and antiplatelet therapy in patients with AF were included. The primary outcomes were the rates of stroke and systemic embolism...
January 2015: Medicine (Baltimore)
https://read.qxmd.com/read/25426077/computational-investigation-of-potential-dosing-schedules-for-a-switch-of-medication-from-warfarin-to-rivaroxaban-an-oral-direct-factor-xa-inhibitor
#45
JOURNAL ARTICLE
Rolf Burghaus, Katrin Coboeken, Thomas Gaub, Christoph Niederalt, Anke Sensse, Hans-Ulrich Siegmund, Wolfgang Weiss, Wolfgang Mueck, Takahiko Tanigawa, Jörg Lippert
The long-lasting anticoagulant effect of vitamin K antagonists can be problematic in cases of adverse drug reactions or when patients are switched to another anticoagulant therapy. The objective of this study was to examine in silico the anticoagulant effect of rivaroxaban, an oral, direct Factor Xa inhibitor, combined with the residual effect of discontinued warfarin. Our simulations were based on the recommended anticoagulant dosing regimen for stroke prevention in patients with atrial fibrillation. The effects of the combination of discontinued warfarin plus rivaroxaban were simulated using an extended version of a previously validated blood coagulation computer model...
2014: Frontiers in Physiology
https://read.qxmd.com/read/25554497/safety-of-venous-thromboembolism-prophylaxis-with-fondaparinux-in-ischemic-stroke
#46
JOURNAL ARTICLE
C T Hackett, R S Ramanathan, K Malhotra, M R Quigley, K M Kelly, M Tian, J Protetch, C Wong, D G Wright, A H Tayal
INTRODUCTION: Unfractionated heparin (UFH), low molecular weight heparin or fondaparinux are recommended for venous thromboembolism (VTE) prophylaxis in acutely ill medical patients. There are limited data on the safety of fondaparinux for VTE prophylaxis in ischemic stroke. We examined adverse event frequency in hospitalized patients with ischemic stroke who received VTE prophylaxis with fondaparinux versus UFH. MATERIALS AND METHODS: We performed a propensity score matched analysis on a retrospective cohort of 644 consecutive patients with acute ischemic stroke receiving fondaparinux (n=322) or UFH (n=322) for VTE prophylaxis...
February 2015: Thrombosis Research
https://read.qxmd.com/read/25515959/fondaparinux-for-the-treatment-of-suspected-heparin-induced-thrombocytopenia-a-propensity-score-matched-study
#47
JOURNAL ARTICLE
Matthew Kang, Majed Alahmadi, Sonja Sawh, Michael J Kovacs, Alejandro Lazo-Langner
Current guidelines for heparin-induced thrombocytopenia (HIT) management recommend heparin cessation and switching to a nonheparin anticoagulant (ie, argatroban, danaparoid) upon clinical suspicion. Fondaparinux may be effective but information supporting its use is limited. We retrospectively evaluated 239 patients who received a nonheparin anticoagulant (fondaparinux = 133, danaparoid = 59, and argatroban = 47) for suspected or confirmed HIT. A propensity score was constructed based on age, gender, creatinine, 4T scores, and comorbidity index, and used to match 133 patients to 60 controls...
February 5, 2015: Blood
https://read.qxmd.com/read/25468718/is-there-a-rationale-for-treatment-of-chronic-liver-disease-with-antithrombotic-therapy
#48
REVIEW
Greg C G Hugenholtz, Patrick G Northup, Robert J Porte, Ton Lisman
Recent advances in the understanding of the coagulopathy in chronic liver disease have provided a strong support for anticoagulation as a new therapeutic paradigm for patients with cirrhosis. Laboratory studies indicate that the net effect of changes in hemostasis in many patients with chronic liver disease is a hypercoagulable status. In turn, clinical thrombosis is increasingly recognized as a complication of liver disease. When occurring within the liver, thrombosis may even progress the disease course. Exciting preliminary data regarding the potential of low-molecular-weight heparin to slow down the progression of liver disease indicate that this class of drugs may improve outcome without a major increase in bleeding risk...
March 2015: Blood Reviews
https://read.qxmd.com/read/25472710/perioperative-bridging-anticoagulation-during-dabigatran-or-warfarin-interruption-among-patients-who-had-an-elective-surgery-or-procedure-substudy-of-the-re-ly-trial
#49
JOURNAL ARTICLE
James D Douketis, Jeff S Healey, Martina Brueckmann, John W Eikelboom, Michael D Ezekowitz, Mandy Fraessdorf, Herbert Noack, Jonas Oldgren, Paul Reilly, Alex C Spyropoulos, Lars Wallentin, Stuart J Connolly
In patients with atrial fibrillation (AF) who require interruption of dabigatran or warfarin for an elective surgery/procedure, the risks and benefits of perioperative bridging anticoagulation is uncertain.We accessed the database from RE-LY, a randomised trial comparing dabigatran with warfarin for stroke prevention in AF, to assess the potential benefits and risks of bridging. In patients who had a first interruption of dabigatran or warfarin for an elective surgery/procedure, we compared the risk for major bleeding (MB), stroke or systemic embolism (SSE) and any thromboembolism (TE) in patients who were bridged or not bridged during the period of seven days before until 30 days after surgery/procedure...
March 2015: Thrombosis and Haemostasis
https://read.qxmd.com/read/25472735/heparin-bridging-in-warfarin-anticoagulation-therapy-initiation-could-increase-bleeding-in-non-valvular-atrial-fibrillation-patients-a-multicenter-propensity-matched-analysis
#50
MULTICENTER STUDY
T-H Kim, J-Y Kim, H-S Mun, H-Y Lee, Y H Roh, J-S Uhm, H-N Pak, M-H Lee, B Joung
BACKGROUND: The efficacy of heparin-bridging therapy during the initiation of oral anticoagulation therapy (OAC) in non-valvular atrial fibrillation (NVAF) is unclear. OBJECTIVES: To evaluate the efficacy and the safety of heparin-bridging therapy during OAC initiation in NVAF patients. PATIENTS/METHODS: This study included 5327 consecutive warfarin-naïve NVAF patients who received OAC that was initiated with (n = 1053) or without (n = 4274) heparin bridging at four tertiary hospitals...
February 2015: Journal of Thrombosis and Haemostasis: JTH
https://read.qxmd.com/read/25495417/new-oral-anticoagulants-for-nonvalvular-atrial-fibrillation-in-the-elderly-limited-applicability-in-primary-care
#51
REVIEW
Wim Opstelten, Maureen van den Donk, Ton Kuijpers, Jako Burgers
BACKGROUND: Based on the results from randomized controlled trials (RCTs), new oral anticoagulants (NOACs) seem attractive alternatives to vitamin K antagonists (VKAs) because of their effectiveness, safety, and ease of use. However, the use of NOACs in unselected elderly patients with atrial fibrillation (AF) in primary care is arguable. OBJECTIVES: To assess the evidence for the effectiveness and safety of NOACs compared with VKAs in elderly patients with nonvalvular AF in primary care...
June 2015: European Journal of General Practice
https://read.qxmd.com/read/25499352/thromboembolic-risk-in-the-initiation-switch-and-interruption-re-initiation-of-oral-anticoagulants-do-newcomers-improve-outcomes-insights-from-a-meta-analysis-of-rcts
#52
LETTER
Daniel Caldeira, João Costa, Joaquim J Ferreira, Fausto J Pinto
No abstract text is available yet for this article.
November 15, 2014: International Journal of Cardiology
https://read.qxmd.com/read/25499873/use-and-outcomes-associated-with-bridging-during-anticoagulation-interruptions-in-patients-with-atrial-fibrillation-findings-from-the-outcomes-registry-for-better-informed-treatment-of-atrial-fibrillation-orbit-af
#53
JOURNAL ARTICLE
Benjamin A Steinberg, Eric D Peterson, Sunghee Kim, Laine Thomas, Bernard J Gersh, Gregg C Fonarow, Peter R Kowey, Kenneth W Mahaffey, Matthew W Sherwood, Paul Chang, Jonathan P Piccini, Jack Ansell
BACKGROUND: Temporary interruption of oral anticoagulation for procedures is often required, and some propose using bridging anticoagulation. However, the use and outcomes of bridging during oral anticoagulation interruptions in clinical practice are unknown. METHODS AND RESULTS: The Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry is a prospective, observational registry study of US outpatients with atrial fibrillation...
February 3, 2015: Circulation
https://read.qxmd.com/read/25500296/evaluating-time-in-therapeutic-range-for-hemodialysis-patients-taking-warfarin
#54
JOURNAL ARTICLE
Laura M Quinn, Robert Richardson, Karen J Cameron, Marisa Battistella
Warfarin is frequently used in the hemodialysis (HD) population for atrial fibrillation (AF) and venous thromboembolism (VTE); however, there is insufficient evidence to support this practice. Given that HD patients have 3 - 10 times the risk for both stroke and bleeding than the general population, anticoagulation in these patients is controversial. Time in therapeutic range (TTR) is accepted as a surrogate outcome of clinical effectiveness and safety of warfarin. The primary objective of this study was to evaluate TTR in an HD population...
February 2015: Clinical Nephrology
https://read.qxmd.com/read/25506433/cheating-the-cha2ds2-vasc-score-thromboembolism-in-apical-hypertrophic-cardiomyopathy
#55
JOURNAL ARTICLE
Robin A P Weir, Nicola MacKenzie, Colin J Petrie
Atrial fibrillation increases the risk of systemic thromboembolism in general and stroke in particular. Not all patients who develop atrial fibrillation are at significantly heightened risk of thromboembolic complications, however, with the development of risk scoring systems aiding clinicians in determining whether formal anticoagulation is mandated. The most commonly used contemporary scoring systems-CHADS2 and CHA2DS2-VASc-provide a reliable means of assessing stroke risk, but certain cardiac conditions are associated with an increased incidence of thromboembolism without impacting on these risk scores...
2014: Case Reports in Cardiology
https://read.qxmd.com/read/25512096/cost-effectiveness-of-novel-oral-anticoagulants-for-stroke-prevention-in-atrial-fibrillation-depending-on-the-quality-of-warfarin-anticoagulation-control
#56
JOURNAL ARTICLE
Andrej Janzic, Mitja Kos
BACKGROUND: Vitamin K antagonists, such as warfarin, are standard treatments for stroke prophylaxis in patients with atrial fibrillation. Patient outcomes depend on quality of warfarin management, which includes regular monitoring and dose adjustments. Recently, novel oral anticoagulants (NOACs) that do not require regular monitoring offer an alternative to warfarin. The aim of this study was to evaluate whether cost effectiveness of NOACs for stroke prevention in atrial fibrillation depends on the quality of warfarin control...
April 2015: PharmacoEconomics
https://read.qxmd.com/read/25512338/the-risks-of-thromboembolism-vs-recurrent-gastrointestinal-bleeding-after-interruption-of-systemic-anticoagulation-in-hospitalized-inpatients-with-gastrointestinal-bleeding-a-prospective-study
#57
JOURNAL ARTICLE
N Sengupta, J D Feuerstein, V R Patwardhan, E B Tapper, G A Ketwaroo, A M Thaker, D A Leffler
OBJECTIVES: Anticoagulants carry a significant risk of gastrointestinal bleeding (GIB). Data regarding the safety of anticoagulation continuation/cessation after GIB are limited. We sought to determine the safety and risk of continuation of anticoagulation after GIB. METHODS: We conducted a prospective observational cohort study on consecutive patients admitted to the hospital who had GIB while on systemic anticoagulation. Patients were classified into two groups at hospital discharge after GIB: those who resumed anticoagulation and those who had anticoagulation discontinued...
February 2015: American Journal of Gastroenterology
https://read.qxmd.com/read/23732713/aspirin-versus-low-molecular-weight-heparin-for-extended-venous-thromboembolism-prophylaxis-after-total-hip-arthroplasty-a-randomized-trial
#58
RANDOMIZED CONTROLLED TRIAL
David R Anderson, Michael J Dunbar, Eric R Bohm, Etienne Belzile, Susan R Kahn, David Zukor, William Fisher, Wade Gofton, Peter Gross, Stephane Pelet, Mark Crowther, Steven MacDonald, Paul Kim, Susan Pleasance, Nicki Davis, Pantelis Andreou, Philip Wells, Michael Kovacs, Marc A Rodger, Tim Ramsay, Marc Carrier, Pascal-Andre Vendittoli
BACKGROUND: The role of aspirin in thromboprophylaxis after total hip arthroplasty (THA) is controversial. OBJECTIVE: To compare extended prophylaxis with aspirin and dalteparin for prevention of symptomatic venous thromboembolism (VTE) after THA. DESIGN: Multicenter randomized, controlled trial with a noninferiority design based on a minimal clinically important difference of 2.0%. Randomization was electronically generated; patients were assigned to a treatment group through a Web-based program...
June 4, 2013: Annals of Internal Medicine
https://read.qxmd.com/read/25482425/factor-xi-antisense-oligonucleotide-for-prevention-of-venous-thrombosis
#59
RANDOMIZED CONTROLLED TRIAL
Harry R Büller, Claudette Bethune, Sanjay Bhanot, David Gailani, Brett P Monia, Gary E Raskob, Annelise Segers, Peter Verhamme, Jeffrey I Weitz
BACKGROUND: Experimental data indicate that reducing factor XI levels attenuates thrombosis without causing bleeding, but the role of factor XI in the prevention of postoperative venous thrombosis in humans is unknown. FXI-ASO (ISIS 416858) is a second-generation antisense oligonucleotide that specifically reduces factor XI levels. We compared the efficacy and safety of FXI-ASO with those of enoxaparin in patients undergoing total knee arthroplasty. METHODS: In this open-label, parallel-group study, we randomly assigned 300 patients who were undergoing elective primary unilateral total knee arthroplasty to receive one of two doses of FXI-ASO (200 mg or 300 mg) or 40 mg of enoxaparin once daily...
January 15, 2015: New England Journal of Medicine
https://read.qxmd.com/read/25482334/making-anti-sense-of-factor-xi-in-thrombosis
#60
EDITORIAL
Robert Flaumenhaft
No abstract text is available yet for this article.
January 15, 2015: New England Journal of Medicine
label_collection
label_collection
2840
3
4
2014-12-12 00:46:36
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.